Publications
- Clinical experience with alemtuzuma2016 | Second Faculty of Medicine
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Dysfunction of peripheral somatic and autonomic nervous system in patients with severe forms of Crohn's disease on biological therapy with TNFα inhibitors-A single center study2023 | Second Faculty of Medicine
- IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis2022 | Second Faculty of Medicine
- Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Elevated D-dimer as an immediate response to alemtuzumab treatment2021 | Second Faculty of Medicine
- Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients2020 | Second Faculty of Medicine
- Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS2019 | Second Faculty of Medicine, First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Pegylated inteferon beta 1-a in clinical routine2019 | Second Faculty of Medicine
- Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN beta2017 | Second Faculty of Medicine, First Faculty of Medicine
Loading network view...